Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
|Articles|September 1, 2008
- Pharmaceutical Executive-09-01-2008
- Volume 0
- Issue 0
Industry Audit + Company of the Year 2008
Author(s)Bill Trombetta
Pharm Exec's 7th annual review of the top companies. We slice and dice the numbers to see who's the best a what. (pdf)
Advertisement
Articles in this issue
about 18 years ago
The New Codeabout 18 years ago
Publish or Perishabout 18 years ago
How Do You Solve a Problem Like Manufacturing?about 18 years ago
Foreign Affairsabout 18 years ago
Tapping the Fountabout 18 years ago
The M&A Numbersabout 18 years ago
The Salesforce Software Shiftabout 18 years ago
Unleash the Dragon 2about 18 years ago
Place Your Betsabout 18 years ago
The Orphan OpportunityAdvertisement
Related to this article
Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come first.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
3
FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy
4
Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma
5